Czech researchers warn against routine ‘just in case’ antibiotics

Researchers at Charles University in Prague are warning that routine preventive antibiotic use is helping drive antimicrobial resistance and should be limited to clearly justified cases. The commentary, published in Clinical Microbiology and Infection, urges narrower-spectrum drugs, shorter treatment and stricter evidence-based prescribing.

Why it matters: - Antibiotic prophylaxis can prevent infection in high-risk patients, but overuse can accelerate antimicrobial resistance. - The authors warn that giving antibiotics “just in case” exposes healthy people to unnecessary drug pressure and weakens the long-term value of critical medicines. - The stakes are global as drug-resistant infections continue to drive rising death tolls.

What happened: - Researchers from the Second Faculty of Medicine of Charles University in Prague published a commentary in Clinical Microbiology and Infection. - The paper argues that preventive antibiotic prescribing has expanded too far and should stop being routine in favor of targeted use. - Dr. Marek Stefan, an infectious disease specialist at Charles University, said prophylaxis can be life-saving but must be used cautiously to preserve effectiveness. - Dr. Marcela Krutova, a medical microbiologist at Charles University, said antibiotic use should be strictly evidence-based and should favor narrow-spectrum drugs.

The details: - The commentary examines four clinical scenarios where prophylactic antibiotic use is drawing concern. - One example is routine empiric antibiotic use in viral pneumonia, which the authors say offers limited benefit while exposing large populations to antimicrobial pressure. - A second example is doxycycline post-exposure prophylaxis, or doxy-PEP, used to prevent bacterial sexually transmitted infections. - A third is vancomycin prophylaxis to reduce Clostridioides difficile infections. - A fourth is post-exposure prophylaxis for invasive Group A Streptococcus in household contacts. - For iGAS, the authors cite epidemiological data from the Netherlands suggesting about 580 healthy contacts must be treated to prevent one secondary case. - The iGAS prophylaxis approach often uses WHO “Watch” category antibiotics such as azithromycin or rifampicin. - The authors say those medicines are critical and should be protected through antimicrobial stewardship programs. - The commentary argues that when hundreds of healthy people are treated to prevent one infection, the selective pressure on the human microbiome rises sharply. - The paper says that pressure helps accelerate the emergence of resistant pathogens.

Between the lines: - The commentary is pushing back on a common clinical instinct: if a treatment might help, prescribing it seems safer than withholding it. - The authors argue that, in the antibiotic era, restraint can be the safer choice for public health. - The piece also reflects a broader stewardship message: broad preventive use can trade short-term reassurance for long-term resistance. - The emphasis on WHO Access antibiotics and short durations signals a move toward preserving the strongest drugs for the patients who truly need them.

What's next: - The authors want healthcare systems to reserve prophylaxis for precise, high-risk situations. - They also want prescribers to choose narrow-spectrum antibiotics whenever possible and keep courses as short as possible. - The commentary frames that approach as a way to protect antibiotic effectiveness before resistance worsens further. - More information